{
    "Clinical Trial ID": "NCT00577122",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cohort I: MPA-Alone",
        "  Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.",
        "INTERVENTION 2: ",
        "  Cohort 2: MPA+IdoCM",
        "  Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.",
        "  Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed adenocarcinoma of the breast with measurable locally recurrent or metastatic disease",
        "  Primary tumor must be ER negative and PR negative",
        "  Patients must be post-menopausal",
        "  Patients may have had up to 3 prior chemotherapy regimens for recurrent/metastatic disease",
        "  Adequate organ function as evidenced by laboratory studies outlined in section 3.6 of the protocol",
        "  Patients with treated, asymptomatic brain metastases are eligible provided chronic steroid therapy is not required",
        "Exclusion Criteria:",
        "  Patients must not have extensive pleural effusion or ascites",
        "  Patients must not have history of DVT or pulmonary embolism w/in past 12 mo",
        "  Patients must not have had chemotherapy or hormonal therapy within 2 weeks of study entry",
        "  Patients must not have had radiation therapy within 1 week of study entry."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Clinical Benefit Rate (CR + PR + SD > 6 Months).",
        "  To determine the clinical benefit rate (Complete Response + Partial Response + Stable Disease > 6 months) per Response Evaluation Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer. This will show the percent of patients who had Clinical Benefit and the Exact 95% Confidence Interval.",
        "  Time frame: baseline through end of study, up to 3 years",
        "Results 1: ",
        "  Arm/Group Title: Cohort I: MPA-Alone",
        "  Arm/Group Description: Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.",
        "  Overall Number of Participants Analyzed: 14",
        "  Measure Type: Number",
        "  Unit of Measure: Percent of Participants  7.1        (0.2 to 33.9)",
        "Results 2: ",
        "  Arm/Group Title: Cohort 2: MPA+IdoCM",
        "  Arm/Group Description: Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.",
        "  Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week.",
        "  Overall Number of Participants Analyzed: 16",
        "  Measure Type: Number",
        "  Unit of Measure: Percent of Participants  6.3        (0.2 to 30.2)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/14 (14.29%)",
        "  DEHYDRATION *0/14 (0.00%)",
        "  FRACTURE *1/14 (7.14%)",
        "  RENAL FAILURE *0/14 (0.00%)",
        "  DYSPNEA (SHORTNESS OF BREATH) *0/14 (0.00%)",
        "  ASPIRATION *0/14 (0.00%)",
        "  HYPOXIA *0/14 (0.00%)",
        "  PNEUMOTHORAX *1/14 (7.14%)",
        "Adverse Events 2:",
        "  Total: 2/16 (12.50%)",
        "  DEHYDRATION *1/16 (6.25%)",
        "  FRACTURE *0/16 (0.00%)",
        "  RENAL FAILURE *1/16 (6.25%)",
        "  DYSPNEA (SHORTNESS OF BREATH) *2/16 (12.50%)",
        "  ASPIRATION *1/16 (6.25%)",
        "  HYPOXIA *1/16 (6.25%)",
        "  PNEUMOTHORAX *0/16 (0.00%)"
    ]
}